Posted by Michael Wonder on 26 Feb 2020
Decision to fund ivacaftor (Kalydeco) for people with cystic fibrosis with the G551D mutation
26 February 2020 - PHARMAC is pleased to announce a decision to fund ivacaftor (Kalydeco) for the treatment of people with cystic fibrosis with the G551D mutation (or other class III gating mutations) through an agreement with Vertex Pharmaceuticals.
Ivacaftor tablets and granules will be funded on the Pharmaceutical Schedule (national funding) at a date yet to be determined, following Medsafe approval.
Exceptional circumstances applications from clinicians for individual patients meeting the funding criteria will be considered from 1 March 2020 until such time that ivacaftor is listed on the Pharmaceutical Schedule.
